| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $6,412,262 | 22 | 100 |
| Raben David | Chief Medical Officer | 0 | $0 | 3 | $524,446 | $-524,446 |
| Hyep Ivan | Chief Financial Officer | 0 | $0 | 7 | $1.18M | $-1.18M |
| Mazumdar Claire | Chief Executive Officer | 0 | $0 | 3 | $1.24M | $-1.24M |
| Cohlhepp Ryan | President and COO | 0 | $0 | 5 | $1.6M | $-1.6M |
| Meisner Lara | Chief Legal Officer | 0 | $0 | 4 | $1.87M | $-1.87M |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Over the last 12 months, insiders at Bicara Therapeutics Inc. Common Stock have bought $0 and sold $6.41M worth of Bicara Therapeutics Inc. Common Stock stock.
On average, over the past 5 years, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $6.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,000 shares for transaction amount of $630,000 was made by Flynn James E (Possible Members of 10% Group) on 2024‑09‑17.
| 2025-12-22 | Sale | Hyep Ivan | Chief Financial Officer | 9,200 0.0168% | $18.31 | $168,492 | -8.30% | |
| 2025-12-15 | Sale | Cohlhepp Ryan | President and COO | 12,500 0.0232% | $18.68 | $233,548 | -7.03% | |
| 2025-11-25 | Sale | Raben David | Chief Medical Officer | 906 0.0017% | $18.84 | $17,071 | -5.12% | |
| 2025-11-24 | Sale | Mazumdar Claire | Chief Executive Officer | 41,163 0.0786% | $18.86 | $776,429 | -7.14% | |
| 2025-11-24 | Sale | Hyep Ivan | Chief Financial Officer | 17,795 0.0334% | $18.55 | $330,094 | -7.14% | |
| 2025-11-24 | Sale | Raben David | Chief Medical Officer | 5,500 0.0103% | $18.45 | $101,475 | -7.14% | |
| 2025-11-21 | Sale | Cohlhepp Ryan | President and COO | 12,500 0.0228% | $18.05 | $225,588 | -2.72% | |
| 2025-11-21 | Sale | Hyep Ivan | Chief Financial Officer | 605 0.0011% | $18.15 | $10,981 | -2.72% | |
| 2025-10-15 | Sale | Mazumdar Claire | Chief Executive Officer | 13,289 0.0244% | $18.84 | $250,391 | -9.46% | |
| 2025-10-15 | Sale | Cohlhepp Ryan | President and COO | 12,500 0.0221% | $18.16 | $226,943 | -9.46% | |
| 2025-10-13 | Sale | Mazumdar Claire | Chief Executive Officer | 11,445 0.0214% | $18.92 | $216,545 | -7.75% | |
| 2025-10-09 | Sale | Hyep Ivan | Chief Financial Officer | 6,415 0.0117% | $18.23 | $116,931 | -6.27% | |
| 2025-10-09 | Sale | Raben David | Chief Medical Officer | 22,000 0.0407% | $18.45 | $405,900 | -6.27% | |
| 2025-10-08 | Sale | Hyep Ivan | Chief Financial Officer | 5,627 0.0104% | $18.21 | $102,456 | -4.78% | |
| 2025-10-07 | Sale | Cohlhepp Ryan | President and COO | 10,900 0.0199% | $18.06 | $196,844 | -5.64% | |
| 2025-10-07 | Sale | Hyep Ivan | Chief Financial Officer | 18,244 0.0335% | $18.22 | $332,386 | -5.64% | |
| 2025-10-06 | Sale | Cohlhepp Ryan | President and COO | 39,600 0.0727% | $18.06 | $714,998 | -4.88% | |
| 2025-10-06 | Sale | Hyep Ivan | Chief Financial Officer | 6,514 0.012% | $18.17 | $118,356 | -4.88% | |
| 2025-09-29 | Sale | Meisner Lara | Chief Legal Officer | 33,807 0.0659% | $14.75 | $498,653 | +23.40% | |
| 2025-09-15 | Sale | Meisner Lara | Chief Legal Officer | 15,829 0.0293% | $11.49 | $181,875 | +48.46% |
| Mazumdar Claire | Chief Executive Officer | 309892 0.5657% | $5.19M | 0 | 3 | |
| Cohlhepp Ryan | President and COO | 189141 0.3453% | $3.17M | 0 | 5 | |
| Hyep Ivan | Chief Financial Officer | 145355 0.2653% | $2.43M | 0 | 7 | |
| Raben David | Chief Medical Officer | 35497 0.0648% | $594,574.75 | 0 | 3 | |
| Meisner Lara | Chief Legal Officer | 0 0% | $0 | 0 | 4 | |
| RA CAPITAL MANAGEMENT, L.P. | 4303418 7.8555% | $72.08M | 1 | 0 | <0.0001% | |
| Flynn James E | Possible Members of 10% Group | 897587 1.6385% | $15.03M | 1 | 0 | <0.0001% |
$28,907,358 | 35 | 41.41% | $913.34M | |
$31,271,604 | 28 | 28.69% | $1.11B | |
$49,930,821 | 19 | 34.14% | $1.1B | |
$21,945,105 | 15 | -26.51% | $1.09B | |
$48,220,484 | 14 | 2.13% | $1.05B | |
$26,254,270 | 14 | 24.18% | $1.01B | |
$103,194,328 | 13 | 9.02% | $1.04B | |
$133,809,976 | 13 | 31.29% | $895.69M | |
$278,247,340 | 12 | 58.08% | $843.1M | |
$1,229,070 | 10 | 23.53% | $851.51M | |
$5,794,001 | 10 | 23.26% | $1.08B | |
$1,580,951 | 9 | -14.18% | $880.01M | |
$160,798,946 | 8 | -3.92% | $827.63M | |
$1,229,547 | 7 | 11.98% | $836.25M | |
$15,652,720 | 6 | -4.77% | $913.25M | |
$21,792,890 | 6 | 75.72% | $1.05B | |
$40,959,889 | 5 | -1.88% | $996.61M | |
$1,148,916 | 3 | -35.10% | $844.69M | |
Bicara Therapeutics Inc. Common Stock (BCAX) | $33,624,000 | 2 | -50.37% | $917.6M |
| Increased Positions | 63 | +55.26% | 3M | +6.59% |
| Decreased Positions | 46 | -40.35% | 4M | -8.49% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 16 | Sold Out | 3M | Sold Out |
| Total Postitions | 131 | +14.91% | 50M | -1.9% |
| Ra Capital Management, L.P. | $113,939.00 | 12.65% | 6.96M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $85,454.00 | 9.49% | 5.22M | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $83,538.00 | 9.27% | 5.1M | +100,000 | +2% | 2025-09-30 |
| Red Tree Management, Llc | $51,933.00 | 5.77% | 3.17M | 0 | 0% | 2025-09-30 |
| Tpg Gp A, Llc | $49,311.00 | 5.47% | 3.01M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $44,199.00 | 4.91% | 2.7M | +159,957 | +6.3% | 2025-09-30 |
| Deep Track Capital, Lp | $39,749.00 | 4.41% | 2.43M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $37,867.00 | 4.2% | 2.31M | +200,469 | +9.49% | 2025-09-30 |
| Omega Fund Management, Llc | $36,112.00 | 4.01% | 2.2M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $36,051.00 | 4% | 2.2M | +195,667 | +9.76% | 2025-09-30 |